Antibody-Drug Conjugates and Immunotoxins

From Pre-Clinical Development to Therapeutic Applications

Editors:

ISBN: 978-1-4614-5455-7 (Print) 978-1-4614-5456-4 (Online)

Table of contents (19 chapters)

  1. Front Matter

    Pages i-ix

  2. Introduction and Development Perspectives

    1. Front Matter

      Pages 1-1

    2. No Access

      Book Chapter

      Pages 3-22

      Antibody Directed Delivery for Treatment of Cancer: Antibody Drug Conjugates and Immunotoxins

    3. No Access

      Book Chapter

      Pages 23-38

      Antibody–Drug Conjugate Development

  3. Development of Antibody-Drug Conjugates

    1. Front Matter

      Pages 39-39

    2. No Access

      Book Chapter

      Pages 41-56

      Assay Methodologies and Challenges

    3. No Access

      Book Chapter

      Pages 57-75

      Clinical Pharmacology Strategies in the Development of Antibody–Drug Conjugates

    4. No Access

      Book Chapter

      Pages 77-90

      Predictive Biomarkers for Antibody–Drug Conjugates

  4. Selection of Cytotoxic Agents

    1. Front Matter

      Pages 91-91

    2. No Access

      Book Chapter

      Pages 93-115

      Factors Involved in the Design of Cytotoxic Payloads for Antibody–Drug Conjugates

    3. No Access

      Book Chapter

      Pages 117-135

      Linker Technology and Impact of Linker Design on ADC Properties

  5. Antibody-Drug Conjugates for Hematologic Malignancies

    1. Front Matter

      Pages 137-137

    2. No Access

      Book Chapter

      Pages 139-147

      Antibody–Drug Conjugates for the Treatment of B-Cell Malignancies

    3. No Access

      Book Chapter

      Pages 149-160

      Targeting CD19 with SAR3419, an anti-CD19-Maytansinoid Conjugate for the Treatment of B Cell Malignancies

    4. No Access

      Book Chapter

      Pages 161-175

      Brentuximab Vedotin (SGN-35) for CD30-Positive Malignancies

  6. Antibody-Drug Conjugates for Solid Tumors

    1. Front Matter

      Pages 177-177

    2. No Access

      Book Chapter

      Pages 179-210

      Trastuzumab Emtansine (T-DM1) for the Treatment of HER2-Positive Cancer with a Focus on Breast Cancer

    3. No Access

      Book Chapter

      Pages 211-220

      CDX-011 (Glembatumumab Vedotin, CR011-vcMMAE)

    4. No Access

      Book Chapter

      Pages 221-239

      Case Study: An Antibody–Drug Conjugate Targeting MUC16 for Ovarian Cancer

    5. No Access

      Book Chapter

      Pages 241-253

      EphA2 Immunoconjugate

    6. No Access

      Book Chapter

      Pages 255-272

      Anti-PSMA Antibody-Drug Conjugates and Immunotoxins

    7. No Access

      Book Chapter

      Pages 273-293

      Targeting CD56 (NCAM)-Expressing Neoplasms with Lorvotuzumab Mertansine

  7. Metabolism

    1. Front Matter

      Pages 295-295

    2. No Access

      Book Chapter

      Pages 297-316

      Studies on the Metabolism of Antibody–Drug Conjugates

  8. Immunotoxins

    1. Front Matter

      Pages 317-317

    2. No Access

      Book Chapter

      Pages 319-348

      Design, Development, and Characterization of Recombinant Immunotoxins Targeting HER2/neu

    3. No Access

      Book Chapter

      Pages 349-367

      The Preclinical and Clinical Evaluation of VB6-845: An Immunotoxin with a De-Immunized Payload for the Systemic Treatment of Solid Tumors

  9. Back Matter

    Pages 369-375